A randomised, open-label, multicentre, efficacy and safety study examining the effects on viral kinetics of all-trans retinoic acid (tretinoin) (Vesanoid) in combination with pegylated interferon alpha-2a (Pegasys) and ribavirin (Copegus) therapy in patients with genotype 1-chronic hepatitis C and non-response to a previous course of peg-interferon alpha/ribavirin combination (ATRACTION)
Latest Information Update: 16 Jun 2021
At a glance
- Drugs Tretinoin (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Pharmacodynamics
- Acronyms ATRACTION; MZ-ATRACTION
- 31 Oct 2010 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
- 13 Nov 2007 New trial record.